Journal ArticleDOI
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
Dirk Schadendorf,Dirk Schadendorf,Georgina V. Long,Georgina V. Long,Georgina V. Long,Daniil Stroiakovski,Boguslawa Karaszewska,Axel Hauschild,Evgeny Levchenko,Vanna Chiarion-Sileni,Jacob Schachter,Claus Garbe,Caroline Dutriaux,Helen Gogas,Mario Mandalà,John B. A. G. Haanen,Céleste Lebbé,Andrzej Mackiewicz,Piotr Rutkowski,Jean-Jacques Grob,Paul Nathan,Antoni Ribas,Michael A. Davies,Ying Zhang,Mathilde Kaper,Bijoyesh Mookerjee,Jeffrey J. Legos,Keith T. Flaherty,Caroline Robert +28 more
Reads0
Chats0
TLDR
Using the largest phase 3 data set available for BRAF/MEK inhibitor combination therapy in melanoma, results demonstrate that durable responses lasting ≥3 years are possible in subsets of patients with BRAF-mutant melanoma receiving D + T.About:
This article is published in European Journal of Cancer.The article was published on 2017-09-01. It has received 137 citations till now. The article focuses on the topics: Dabrafenib & Trametinib.read more
Citations
More filters
Journal ArticleDOI
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert,Jean J. Grob,Daniil Stroyakovskiy,Boguslawa Karaszewska,Axel Hauschild,Evgeny Levchenko,Vanna Chiarion Sileni,Jacob Schachter,Claus Garbe,Igor Bondarenko,Helen Gogas,Mario Mandalà,John B A G Haanen,C. Lebbé,Andrzej Mackiewicz,Piotr Rutkowski,Paul Nathan,Antoni Ribas,Michael A. Davies,Keith T. Flaherty,Paul Burgess,Monique Tan,Eduard Gasal,Maurizio Voi,Dirk Schadendorf,Georgina V. Long +25 more
TL;DR: First-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Journal ArticleDOI
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Antoni Ribas,Donald P. Lawrence,Victoria Atkinson,Sachin Agarwal,Wilson H. Miller,Wilson H. Miller,Matteo S. Carlino,Rosalie Fisher,Georgina V. Long,F. Stephen Hodi,Jennifer Tsoi,Catherine S. Grasso,Bijoyesh Mookerjee,Qing Zhao,Razi Ghori,Blanca Homet Moreno,Nageatte Ibrahim,Omid Hamid +17 more
TL;DR: This study suggests that this triple-combined therapy may benefit a subset of patients with BRAFV600-mutated metastatic melanoma by increasing the frequency of long-lasting antitumor responses.
Journal ArticleDOI
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo A. Ascierto,Pier Francesco Ferrucci,Rosalie Fisher,Michele Del Vecchio,Victoria Atkinson,Henrik Schmidt,Jacob Schachter,Paola Queirolo,Georgina V. Long,Anna Maria Di Giacomo,Inge Marie Svane,Michal Lotem,Gil Bar-Sela,Félix Couture,Bijoyesh Mookerjee,Razi Ghori,Nageatte Ibrahim,Blanca Homet Moreno,Antoni Ribas +18 more
TL;DR: A randomized phase 2 trial testing triple combination of BRAF, MEK and PD-1 inhibition as first-line therapy in patients with BRAF-mutant melanoma shows durable responses and encouraging progression-free survival.
Journal ArticleDOI
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Richard W. Joseph,Jeroen Elassaiss-Schaap,Richard F. Kefford,Richard F. Kefford,Wen-Jen Hwu,Jedd D. Wolchok,Anthony M. Joshua,Antoni Ribas,F. Stephen Hodi,Omid Hamid,Caroline Robert,Adil Daud,Roxana S. Dronca,Peter Hersey,Jeffrey S. Weber,Amita Patnaik,Dinesh P. de Alwis,Andrea Marie Perrone,Jin Zhang,S. Peter Kang,Scot Ebbinghaus,Keaven M. Anderson,Tara C. Gangadhar +22 more
TL;DR: In this paper, the authors assess the association of baseline tumor size with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827).
Journal ArticleDOI
Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina V. Long,Zeynep Eroglu,Jeffrey R. Infante,Sapna Pradyuman Patel,Adil Daud,Douglas B. Johnson,Rene Gonzalez,Richard F. Kefford,Richard F. Kefford,Omid Hamid,Lynn M. Schuchter,Jonathan Cebon,William H. Sharfman,Robert R. McWilliams,Mario Sznol,Suman Redhu,Eduard Gasal,Bijoyesh Mookerjee,Jeffrey S. Weber,Keith T. Flaherty +19 more
TL;DR: This 5-year analysis represents the longest follow-up to date with BRAF + MEK inhibitor combination therapy in BRAF V600-mutant MM and elicits durable plateaus of long-term OS and progression-free survival that last ≥ 5 years in some patients with MM.
References
More filters
Book
Analysis of Survival Data
David Cox,D. Oakes +1 more
TL;DR: In this article, the authors give a concise account of the analysis of survival data, focusing on new theory on the relationship between survival factors and identified explanatory variables and conclude with bibliographic notes and further results that can be used for student exercises.
Book
Modeling Survival Data: Extending the Cox Model
TL;DR: A Cox Model-based approach was used to estimate the Survival and Hazard Functions and the results confirmed the need for further investigation into the role of natural disasters in shaping survival rates.
Journal ArticleDOI
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert,Caroline Robert,Caroline Robert,Jacob Schachter,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Omid Hamid,Christine Mateus,Christine Mateus,Ronnie Shapira-Frommer,Ronnie Shapira-Frommer,Michele Kosh,Honghong Zhou,Nageatte Ibrahim,Scot Ebbinghaus,Antoni Ribas +26 more
TL;DR: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Journal ArticleDOI
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch,Jeffrey E. Gershenwald,Seng-Jaw Soong,John F. Thompson,Michael B. Atkins,David R. Byrd,Antonio C. Buzaid,Alistair J. Cochran,Daniel G. Coit,Shouluan Ding,Alexander M.M. Eggermont,Keith T. Flaherty,Phyllis A. Gimotty,John M. Kirkwood,Kelly M. McMasters,Martin C. Mihm,Donald L. Morton,Merrick I. Ross,Arthur J. Sober,Vernon K. Sondak +19 more
TL;DR: Revised melanoma staging system has been made that reflect the improved understanding of this disease and will be formally incorporated into the seventh edition of the AJCC Cancer Staging Manual and implemented by early 2010.
Journal ArticleDOI
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S. Weber,Sandra P. D'Angelo,David R. Minor,F. Stephen Hodi,Ralf Gutzmer,Bart Neyns,Christoph Hoeller,Nikhil I. Khushalani,Wilson H. Miller,Christopher D. Lao,Gerald P. Linette,Luc Thomas,Paul Lorigan,Kenneth F. Grossmann,Jessica C. Hassel,Michele Maio,Mario Sznol,Paolo A. Ascierto,Peter Mohr,Bartosz Chmielowski,Alan H. Bryce,Inge Marie Svane,Jean-Jacques Grob,Angela M. Krackhardt,Christine Horak,Alexandre Lambert,Arvin Yang,James Larkin +27 more
TL;DR: Nivolumab led to a greater proportion of patients achieving an objective response and fewer toxic effects than with alternative available chemotherapy regimens for patients with advanced melanoma that has progressed after ipilimumab or ipilicumab and a BRAF inhibitor.
Related Papers (5)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Piotr Rutkowski,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,John Wagstaff,Dirk Schadendorf,Pier Francesco Ferrucci,Michael Smylie,Reinhard Dummer,Andrew F. Hill,David Hogg,John B. A. G. Haanen,Matteo S. Carlino,Oliver Bechter,Michele Maio,Ivan Marquez-Rodas,Massimo Guidoboni,Grant A. McArthur,Céleste Lebbé,Paolo A. Ascierto,Georgina V. Long,Jonathan Cebon,Jeffrey A. Sosman,Michael A. Postow,Margaret K. Callahan,Dana Walker,Linda Rollin,Rafia Bhore,F. Stephen Hodi,James Larkin,James Larkin +33 more
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert,Boguslawa Karaszewska,Jacob Schachter,Piotr Rutkowski,Andrzej Mackiewicz,Daniil Stroiakovski,Michael Lichinitser,Reinhard Dummer,Florent Grange,Laurent Mortier,Vanna Chiarion-Sileni,Kamil Drucis,Ivana Krajsová,Axel Hauschild,Paul Lorigan,Pascal Wolter,Georgina V. Long,Keith T. Flaherty,Paul Nathan,Antoni Ribas,Antoni Ribas,Anne-Marie Martin,Peng Sun,Wendy A. Crist,Jeff Legos,Stephen D. Rubin,Shonda M Little,Dirk Schadendorf +27 more
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin,Paolo A. Ascierto,Brigitte Dréno,Victoria Atkinson,Gabriella Liszkay,Michele Maio,Mario Mandalà,Lev V. Demidov,Daniil Stroyakovskiy,Luc Thomas,Luis de la Cruz-Merino,Caroline Dutriaux,Claus Garbe,Mika A. Sovak,Ilsung Chang,Nicholas Choong,Stephen P. Hack,Grant A. McArthur,Antoni Ribas +18 more
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Wilson H. Miller,Eckhart Kaempgen,Salvador Martín-Algarra,Boguslawa Karaszewska,Cornelia Mauch,Vanna Chiarion-Sileni,Anne-Marie Martin,Suzanne Swann,Patricia Haney,Beloo Mirakhur,Mary E. Guckert,Vicki L. Goodman,Paul B. Chapman +20 more